ઑર્કિડ ફાર્મા શેર કિંમત

Pharmaceuticals company Orchid Pharma announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, the company reported Revenue from operations of Rs 23,760.73 lakh, reflecting a growth of 14.64% QoQ from Rs 20,726.70 lakh in Q3FY26 and a marginal increase of 0.05% YoY from Rs 23,747.87 lakh in Q4FY25. Total Income: Total Income for Q4FY26 stood at Rs 24,494.92 lakh, an increase of 15.07% QoQ from Rs 21,287.64 lakh and a growth of 1.48% YoY from Rs 24,137.59 lakh. Net Profit: The company recorded a Net Profit of Rs 2,278.51 lakh in Q4FY26, marking a swing from a loss of Rs 1,214.64 lakh in Q3FY26 and a growth of 19.08% YoY compared to Rs 1,913.35 lakh in Q4FY25. Annual Revenue: For the full year FY26, Revenue from operations reached Rs 81,132.73 lakh, representing a decline of 12.00% YoY from Rs 92,192.59 lakh in FY25. Annual Net Profit: Annual Consolidated Net Profit for FY26 was Rs 2,120.83 lakh, witnessing a significant decrease of 77.85% YoY compared to Rs 9,575.83 lakh in the previous year. Earnings Per Share (EPS): Annual basic and diluted EPS for FY26 stood at Rs 4.05, compared to Rs 19.65 in FY25. Standalone Financial Highlights: Revenue from Operations: Standalone Revenue from operations for Q4FY26 was Rs 23,760.73 lakh, an increase of 14.64% QoQ from Rs 20,726.70 lakh and up 0.05% YoY from Rs 23,747.87 lakh. Total Income: Standalone Total Income for the quarter was Rs 25,090.36 lakh, showing a growth of 15.17% QoQ and 2.94% YoY. Net Profit: Standalone Net Profit for Q4FY26 stood at Rs 3,060.37 lakh, a swing from a loss of Rs 582.43 lakh in Q3FY26 and an increase of 9.89% YoY from Rs 2,784.87 lakh. Annual Performance: For the full year FY26, standalone Revenue from operations was Rs 81,132.73 lakh (down 12.00% YoY) and standalone Net Profit was Rs 4,520.79 lakh (down 57.54% YoY). Business Highlights: Segment Performance: The company operates under a single operating segment, namely "Pharmaceuticals", and therefore no separate segment reporting is applicable. Strategic Acquisitions: The company successfully completed the 100% asset acquisition of Allecra Therapeutics GmbH (Germany) and Allecra Therapeutics SAS (France). This provides the company with 100% global ownership of the antibiotic molecule Enmetazobactam (Brand Name: EXBLIFEP; Orblicef in India), marking the full repatriation of the first novel antibiotic molecule discovered in India. Corporate Amalgamation: A petition has been submitted to the Hon'ble NCLT for the amalgamation of the Holding Company, Dhanuka Laboratories Limited, with the company. The matter was reserved for pronouncement of order following a hearing on March 18, 2026. Qualified Audit Opinion: The consolidated financial results received a qualified opinion from the statutory auditors as certain subsidiaries based in the USA were consolidated based on unaudited financial statements, reflecting total assets of Rs 385.59 lakh as of March 31, 2026. QIP Fund Utilization: Out of the net proceeds of Rs 39,180 lakh raised via Qualified Institutional Placement (QIP), the company has utilized Rs 33,256 lakh. A balance of Rs 6,198 lakh is currently kept in fixed deposits. Labour Code Provisions: The company assessed the impact of the new Labour Codes and determined incremental liabilities for past service cost at Rs 657.35 lakh. Consequently, an excess provision of Rs 53.92 lakh made in the December 2025 quarter was reversed in Q4FY26 under "Exceptional items". Result PDF

• ટ્રેન્ડલાઇન
• 2 અઠવાડિયા 6 દિવસ પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની ઑર્કિડ ફાર્માએ Q3FY26 પરિણામોની આવકની જાહેરાત કરી: Q3FY25 દરમિયાન ₹21,734.25 લાખ સામે ₹20,726.7 લાખ, -5% બદલો. પીબીટી: Q3FY25 દરમિયાન રૂ. 2,245 લાખ સામે રૂ. -1,214.64 લાખ. પીએટી: Q3FY25 દરમિયાન રૂ. 2,077.51 લાખ સામે રૂ. -1,261.35 લાખ. ઇપીએસ: Q3FY26 માટે ₹ -2.49. પરિણામની PDF

• ટ્રેન્ડલાઇન
• 4 મહિના પહેલાં

નકારાત્મક કમાણીના માર્ગ હોવા છતાં ઑર્કિડ ફાર્માનું વેલ્યુએશન 67x FY26 P/E પર સમૃદ્ધ રહે છે, સિસ્ટમેટિક્સ ઉમેરે છે.

• એનડીટીવી પ્રોફિટ
• 7 મહિના પહેલાં